Consun Pharmaceutical Group Limited (FRA:C1P)

Germany flag Germany · Delayed Price · Currency is EUR
1.850
+0.040 (2.21%)
At close: Mar 27, 2026
Market Cap1.62B +111.6%
Revenue (ttm)416.13M +15.2%
Net Income131.27M +18.4%
EPS0.15 +15.6%
Shares Outn/a
PE Ratio12.35
Forward PE10.41
Dividend0.07 (3.77%)
Ex-Dividend DateSep 4, 2025
Volumen/a
Average Volume180
Open1.860
Previous Close1.810
Day's Range1.850 - 1.860
52-Week Range0.875 - 2.180
Betan/a
RSI53.21
Earnings DateMar 26, 2026

About FRA:C1P

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass... [Read more]

Industry Pharmaceutical Preparations
Founded 1997
Employees 3,073
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol C1P

Financial Performance

In 2025, FRA:C1P's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY Financial Statements